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Catalytic cleavage of 10–23 DNAzyme functionalized with an amino group 291. Introduction
10–23 DNAzyme, an unnatural DNA enzyme obtained by
in vitro selection from a DNA reservoir, is a sequence-speciﬁc
RNA-cleaving DNA molecule1,2. Compared with ribozymes, its
high chemical and biological stability and convenient synthesis
seem to be more in favor of therapeutic and other biotechnolo-
gical applications. Indeed, many efforts have been made for its
applications, including the suppression of speciﬁc disease-related
genes3–16, nucleic acid structural and functional analysis, and
other applications like DNA nanomachine17–24. Improvement of
its intrinsic characteristics, such as cleavage site preferences,
cleavage efﬁciencies, and high-level Mg2þ-dependence, as well as
nuclease stability and efﬁcient delivery for its optimal activities
has been the focuses of many researches25–34. Some DNAyzmes
with protein-like functional groups were selected in vitro, which
could conduct RNA-cleavage reaction with M2þ-indepen-
dence29,34–37. 10–23 DNAyzme analogs with M2þ-independence
was obtained, but with a sacriﬁce of cleavage efﬁciency. Because
an insight into the catalytic mechanism of the DNAzyme is not
yet available38,39, new random selections and chemical modiﬁca-
tions for more efﬁcient variants are still currently necessary40–44.
As we have reported, screening with 7-substituted 8-aza-7-deaza-
20-deoxyadenosine derivatives in the positions of ﬁve dA residues
(A5, A9, A11, A12, and A15) led to the ﬁnding that A9 is the
right position for 7-substituted 8-aza-7-deaza-deoxyadenosine
analogs, by which N8 atom, 7-subustituted phenethyl, 3-hydro-
xypropyl and 3-aminopropyl were introduced and positive effect
on cleavage rate was always observed (Fig. 1)45. Especially,
replacement of 7-(3-aminopropyl)-8-aza-7-deaza-20-deoxyadeno-
sine (1) at A9 position promised a 12-fold increase of cleavage
rate. We postulated that the location of the amino group by this
modiﬁcation contributed to a most favorable catalytic conforma-
tion. In this study, the effect of this compound in other four
non-dA positions were explored, with the aim to evaluate an
appropriate position for the positive role of the extra amino
group of compound 1 in the catalytic core of 10–23 DNAzyme.Figure 1 Left: the complex of 10–23 DNAzyme and its DNA–
RNA–DNA substrate. Bold letters represent the RNA residues in
the substrate. The arrow denotes the cleavage site on the
substrate. Right: compound 1.
Table 1 MALDI-TOF MS data of 10–23 DNAzyme analogs.
DNAzyme Sequences (50–30)
DZ-1-8 d(tgc tct cca GGC TAG C1A CAA CGA cc
DZ-1-10 d(tgc tct cca GGC TAG CTA 1AA CGA cc
DZ-1-13 d(tgc tct cca GGC TAG CTA CAA 1GA cc
DZ-1-14 d(tgc tct cca GGC TAG CTA CAA C1A cc2. Results and discussion
The oligodeoxynucleotides were synthesized with phosphorami-
dite chemistry. The phosphoramidite of compound 1 was
synthesized according to the published procedure45. The oligo-
deoxynucleotides were puriﬁed by preparative denaturing 20%
polyacrylamide gel electrophoresis (containing 7 M urea) and
desalted with SEP-PAK cartridges. Characterization was per-
formed with MALDI-TOF MS (Table 1). In the 10–23 DNA-
zyme analogs, compound 1 was incorporated into four positions,
instead of T8, C10, C13 and G14, namely, DZ-1-8, DZ-1-10,
DZ-1-13 and DZ-1-14 were obtained, respectively.
In order to demonstrate whether these modiﬁed DNAzymes
could bind the substrate as 10–23 DNAzyme, the Tm of the
complexes of these modiﬁed DNAzymes with the substrate was
evaluated under the conditions for the cleavage reaction (50 mM
Tris–HCl, 2 mM Mg2þ)45, with the chimeric DNA–RNA–DNA
substrate replaced by its corresponding full-DNA substrate D19,
50-d (AGG TGC AGG ATG GAG AGC A)-30 to avoid any
cleavage reactions conducted by DNAzyme itself and nucleases
in the environment. All the complexes have a Tm of 51 1C
(Table 1), very close to that of the complex of 10–23 DNAzyme
and D19 (52 1C). It meant that the chemical modiﬁcations on the
catalytic core could not result in changes on the thermal stability
of the complexes. Furthermore, the temperature of all the
cleavage reactions was set at 37 1C, much lower than the Tm
of DNAyzme-substrate complexes. Therefore, it was suggested
that the changes of cleavage behavior of the modiﬁed DNA-
zymes could be attributed to the inﬂuence of the chemical
modiﬁcations on the cleavage step, instead of the thermal
stability of the complex. The cleavage reaction of these DNA-
zymes on the 32P-labled target DNA–RNA–DNA substrate was
evaluated under single-turnover conditions.45
It has been demonstrated that compound 1 at A9 position
of 10–23 DNAzyme contributed a 12-fold increase of cleavage
rate, DZ-1–9 with kobs of 0.0037 min
1 45. DZ-1–9 is the fastest
DNAzyme in the screening of ﬁve dA residues with compound 1
in the catalytic core of 10–23 DNAzyme. Instead of these ﬁve dA
positions, other residues in the catalytic core were substituted by
compound 1 to explore the possible positive role of the extra
amino group. Firstly, a position shift of compound 1 around A9
was conducted. When compound 1 in DZ-1–9 was shifted to its
50-residue position T8 (DZ-1–8), as shown in Fig. 2, DZ-1–8
could also conduct the reaction like the parent 10–23 DNAzyme,
but with a slower cleavage rate (0.002070.0002/min) (Table 2).
This replacement resulted in moderate loss of activity, compared
with 10–23 DNAzyme, which was not so consistent with
previous observation that T8 is the least conserved residue, any
other canonical residue or even modiﬁed residue replacement
results in little effect on the cleavage of 10–23 DNAzyme40,41.
On the other hand, the replacement of compound 1 at its
30-positioned C10 led to a further decrease of the reaction rate, asMW (calcd.) MW (found)
t gca cct) 10,060.5 10,062.5
t gca cct) 10,075.6 10,077.4
t gca cct) 10,075.6 10,077.0
t gca cct) 10,035.6 10,036.6
Figure 2 The position-dependent effect of compound 1 in the
catalytic loop of 10–23 DNAzyme: at A9 (DZ-1-9, solid dia-
mond)45, at T8 (DZ-1-8, solid triangle), at C10 (DZ-1-10, open
diamond), at C13 (DZ-1-13, open square), at G14 (DZ-1-14, open
triangle), and 10–23 DNAzyme (solid square)45.
Table 2 Observed rate constants of 10–23 DNAzyme and
its analogs measured under single-turnover conditions.
DNAzyme Tm (1C) kobs /min
10–23 DNAzyme 52 0.003770.0000745
DZ-1-9 51 0.04570.00445
DZ-1-8 51 0.002070.0002
DZ-1-10 51 0.001270.0001
DZ-1-13 51 ND
DZ-1-14 51 ND
ND: not detected under present conditions.
Qi Wang et al.30observed with DZ-1–10 (0.001270.0001 min1). It meant that
the occupation of cytosine at this position was necessary38. Up to
now, deletion of C10 or its replacement with other natural or
modiﬁed residues always resulted in moderate to signiﬁcant loss
of cleavage activity.
The amino groups of C13 and G14 have been demonstrated
to be very important for the function of 10–23 DNAzyme38,
their amino groups are supposed to be involved in the reaction
in some way. When an extra amino group was introduced to
these two positions by compound 1; however, such changes led
to a signiﬁcant loss of the catalytic function, as shown by
DZ-1–13 and DZ-1–14 (Fig. 2). It seems that the new
interactions related to compound 1 at these two positions
was detrimental to the reaction, other functional groups in
C13 and G14 as well as their spacial occupation might be
important for their roles in the context of the catalytic loop.
As demonstrated in our work, in the total nine modiﬁed
positions (A5, T8, A9, C10, A11, A12, C13, G14 and A15) in the
catalytic core of 10–23 DNAzyme45, the effect of compound 1
was position-dependent. These observations emphasized the
importance of the location for the extra amino group from
compound 1 and the conservation of the residues deﬁned by
in vitro selection. In other words, the catalytic core of 10–23
DNAyzme is very sensitive to chemical modiﬁcations, no mattermore or less catalytic power of the new DNAzymes. More
importantly, we learnt from these results that A9 is the most
appropriate position for the introduction of 7-substituted 8-aza-
7-deaza-20-deoxyadenosine analogs, up to now. This screening
research promised more efﬁcient deoxyribozymes for practical
applications by chemical functionalization at A9 in the catalytic
core of 10–23 DNAzyme.3. Experimental
3.1. Oligodeoxynucleotides
Oligodeoxynucleotides were synthesized on an ABI 392 DNA/
RNA synthesizer (Applied Biosystems, USA) with the DMT-off
mode, on a 1 mmol scale according to the User Protocol. The
phosphoramidites of canonical residues were purchased from
Proligo (Sigma-Aldrich). The oligodeoxynucleotides were depro-
tected in conc. aq. ammonia for 18 h at 60 1C and puriﬁed by a
20% polyacrylamide/7 M urea denaturing gel. After desalting
with SEP-PAK cartridges (Oasis MAX, C18, Waters, USA), the
product was characterized by MALDI-TOF performed on an
autoﬂex TOF/TOF (BRUKER, Daltonics) with HPA as the
matrix. The chimeric substrate was purchased from Takara
(Dalin, China). Tm measurement was conducted on a Cary-100
Bio UV–Visible spectrophotometer equipped with a Cary tem-
perature controller (Varian, USA)45.
3.2. Cleavage reaction under single-turnover conditions45
Prior to the cleavage reaction, the solution of deoxyribozyme
(2 mM) and the 32P-labeled substrate45 (20 nM) in 50 mM Tris–
HCl (pH 7.4) was denatured at 90 1C for 3 min and cooled to
37 1C. Mg2þ was added to a ﬁnal concnentration of 2 mM,
and the cleavage reaction was initiated. At different time points,
aliquots were taken from the reaction mixture and quenched by an
equal volume of stopping solution (100 mM EDTA, 8M Urea).
The substrate and the cleavage product in the samples were
separated by electrophoresis on a 20% polyacrylamide gel con-
taining 7M urea, and quantiﬁed by the densitometry of the gel
images with a Molecular Dynamics Storm 840 Phosphoimager.
The observed rate constant k were calculated according to the
equation P%¼PN%C  exp [kobst], where P% is the cleavage
percentage of product at time t, PN% is the ﬁnal percentage of
the product at t¼N, C is the difference in P% between t¼N
and t¼0. The data was given as the averaged results of three
independent experiments. Less than 20% variation was observed
for identical experiments performed on different days.
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